DDInter993 DDInter1376
Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Isradipine {u} (Compound) resembles {v} (Compound) Amlodipine
Isradipine {u} (Compound) resembles {v} (Compound) Nimodipine
Isradipine {u} (Compound) treats {v} (Disease) hypertension
Isradipine {u} (Compound) binds {v} (Gene) CYP3A4
Isradipine {u} (Compound) upregulates {v} (Gene) KLHL21
Isradipine {u} (Compound) is included by {v} (Pharmacologic Class) Dihydropyridines
Isradipine {u} (Compound) downregulates {v} (Gene) MT2A
Isradipine {u} (Compound) causes {v} (Side Effect) Visual impairment
Isradipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Simvastatin
Isradipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Isradipine (Compound) resembles Amlodipine (Compound)
Isradipine (Compound) resembles Nimodipine (Compound)
Isradipine (Compound) treats hypertension (Disease)
Isradipine (Compound) binds CYP3A4 (Gene)
Isradipine (Compound) upregulates KLHL21 (Gene)
Isradipine (Compound) is included by Dihydropyridines (Pharmacologic Class)
Isradipine (Compound) downregulates MT2A (Gene)
Isradipine (Compound) causes Visual impairment (Side Effect)
Isradipine may cause a minor interaction that can limit clinical effects when taken with Simvastatin
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab